Emphysema Treatment Market Research, 2032
The global emphysema treatment market was valued at $6.3 billion in 2022, and is projected to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032. Surge in prevalence of emphysema and rise in number of smokers are expected to drive the growth of the emphysema treatment market. For instance, according to 2024 article by American Lung Association, it was estimated that over 3 million people in the U.S. have been diagnosed with emphysema. Furthermore, according to a report by Foundation for a Smoke-Free World, it was reported that prevalence of smoking in India was estimated to be 4.6%.
Key Takeaways
By treatment type, the medication segment was the major shareholder in the emphysema treatment market size in 2022.
On the basis of type, the centriacinar segment is expected to exhibit the fastest market growth during the forecast period.
Depending on end user, the homecare segment acquired the largest emphysema treatment market size in in 2022.
Region wise, North America held the largest market share in 2022; however, Asia-Pacific is expected to witness the highest CAGR during the forecast period.
Emphysema is a chronic and progressive lung condition characterized by damage to the air sacs in the lungs, known as alveoli. This damage leads to the deterioration of the lung tissue and results in decreased elasticity, making it difficult to breathe. The primary cause of emphysema is long-term exposure to irritants, most commonly cigarette smoke, although other factors such as air pollution and genetic predisposition can also contribute. Symptoms of emphysema include shortness of breath, chronic coughing, wheezing, and tightness in the chest. Treatment for emphysema focuses on managing symptoms and slowing down the progression of the disease. Medication, oxygen therapy, and surgery are the therapeutic interventions for emphysema treatment.
Market Dynamics
The emphysema treatment market growth is expected to surge significantly owing to rise in prevalence of emphysema, increase in number of smokers globally, and development of healthcare infrastructure. Furthermore, surge in prevalence of emphysema can be attributed to several factors, including an aging population, widespread tobacco use, exposure to environmental pollutants, and increase in incidence of respiratory infections. According to 2023 report by the National Library of Medicine, it was reported that emphysema is caused by chronic and significant exposure to noxious gases, of which cigarette smoking remains the most common cause.
For instance, according to Center of Disease Control and Prevention, it was reported that in 2021, 11.5% of the U.S. adults smoked cigarette. As smoking rates remain high in many parts of the world and air quality continues to deteriorate in densely populated areas, the incidence of emphysema is expected to rise. As the prevalence of emphysema rises, the demand for effective treatments is expected to surge simultaneously. Thus, rise in the global prevalence of emphysema is expected to significantly contribute toward the growth of the emphysema treatment market growth.
Furthermore, developing healthcare infrastructure is expected to drive the emphysema treatment market opportunity. As countries invest in upgrading their healthcare systems, there emerges a greater emphasis on improving diagnostic capabilities, treatment options, and overall patient care. Enhanced infrastructure enables easier access to specialized medical facilities equipped with state-of-the-art diagnostic tools such as high-resolution computed tomography (HRCT) scanners, pulmonary function testing labs, and bronchoscopy units, facilitating early detection and accurate diagnosis of emphysema. Moreover, robust healthcare infrastructure fosters the establishment of specialized clinics and multidisciplinary healthcare teams comprising pulmonologists, respiratory therapists, and rehabilitation specialists, who collaborate to develop tailored treatment plans for emphysema patients. These plans often encompass a combination of pharmacological interventions, such as bronchodilators and corticosteroids, as well as non-pharmacological approaches like oxygen therapy.
In addition, technological advancements in surgical techniques, including minimally invasive procedures like bronchoscopic lung volume reduction and lung transplantation, along with the increasing adoption of the same within developing economies drive the market growth of the emphysema treatment market forecast. Thus, the development in the healthcare infrastructure is expected to drive the emphysema treatment market.
Moreover, decreasing air quality index has emerged as a significant catalyst of the emphysema treatment market. With air pollution levels on the rise globally, individuals are increasingly exposed to harmful particulate matter and pollutants, exacerbating respiratory conditions like emphysema. Countries in Asia-Pacific have registered significant decrease in the air quality index. For instance, according to 2022 article by the World Bank, it was reported that South Asia is home to 9 of the worlds 10 cities with the worst air pollution, which causes an estimated 2 million premature deaths across the region each year. As the air quality deteriorates, more individuals are diagnosed with emphysema, driving the need for innovative therapies and interventions to alleviate symptoms and improve the quality of life.
Furthermore, rise in R and D activities and new product development are expected to drive the growth of the market. Recent years have seen a surge in innovative therapies and treatment modalities aimed at alleviating symptoms and slowing disease progression. This surge can be attributed to intensified R and D efforts by pharmaceutical companies, biotech firms, and academic institutions, fueled by growing awareness of the disease burden and unmet medical needs. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for chronic obstructive pulmonary disease (COPD) patients in a once-daily regime. These efforts have led to the development of novel medications, advanced inhalation devices, and cutting-edge surgical techniques tailored to address the specific mechanisms underlying emphysema pathology. Thus, rise in R and D activities and new product development are expected to drive emphysema treatment market opportunity.
However, high cost of treatment restrains the growth of the emphysema treatment market. Emphysema requires comprehensive management strategies that often entail a range of medical interventions. From medication regimens to oxygen therapy and, in severe cases, surgical procedures such as lung volume reduction surgery or lung transplantation, the spectrum of treatment options is broad but expensive. For patients, particularly those without adequate insurance coverage or financial resources, accessing these treatments can be a financial challenge, potentially leading to delayed or inadequate care. Moreover, for healthcare systems grappling with escalating healthcare costs, the financial strain of emphysema treatment adds to the broader challenge of resource allocation and sustainability. Thus, high cost of treatment is a significant challenge for the growth of the market.
Segments Overview
The global emphysema treatment market is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy, and surgery. Depending on type, it is segregated into centriacinar, panacinar, and others. On the basis of end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Treatment Type
The medication segment dominated the global emphysema treatment market share in 2022 and is expected to register fastest growth in the forecast period, owing to high adoption of the medication by healthcare professionals as a first line of treatment. In addition, the easy availability and cost effectivity of the medication contribute to its higher adoption.
By Type
The centriacinar segment dominated the global emphysema treatment market share in 2022 and is expected to register the fastest growth in the forecast period, owing to the fact that centriacinar is one of the most prevalent forms of emphysema, particularly among smokers, who represent a significant portion of the population affected by this condition. Centriacinar is characterized by damage primarily to the central or proximal portions of the acinus within the lungs.
By End User
The homecare segment dominated the global emphysema treatment market share in 2022 and is expected to register fastest growth in the forecast period, owing to availability of medications which can be used in home settings and advancements in medical technology that have enabled the development of portable and user-friendly devices for managing emphysema symptoms at home.
By Region
The emphysema treatment market is analyzed across North America, Europe, Asia-Pacific, LAMEA. North America accounted for a major share of the emphysema treatment market in 2022 and is expected to maintain its dominance during the forecast period. This is attributed to advanced medical facilities available in the region and high level of healthcare spending, which facilitates the adoption of novel treatments for emphysema. In addition, extensive R and D activities, along with a supportive regulatory environment, have propelled the development and commercialization of emphysema treatment products in North America. However, Asia-Pacific is expected to register the highest CAGR during the forecast period owing to high prevalence of respiratory conditions such as COPD and decline in air quality index in the region.
Competitive Analysis
Competitive analysis and profiles of the major players in the emphysema treatment industry such as AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Viatris Inc., Inogen, Teva Pharmaceuticals, Koninklijke Philips N.V., and Verona Pharma are provided in this report. These have adopted acquisition, agreement, investment, product launch, product approval, and clinical trials as a key developmental strategies to improve the product portfolio of the emphysema treatment market.
Recent Developments in Emphysema Treatment Industry
In March 2024, AstraZeneca announced the initiation of a phase III trial to investigate the potential effect of triple-combination inhaled therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) on severe cardiopulmonary outcomes, including death, in people with COPD who also have elevated cardiopulmonary risk, irrespective of their exacerbation history.
In January 2024, Verona Pharma Plc. announced it and its wholly owned subsidiary, Verona Pharma, Inc. have entered into a debt financing facility providing the company with access to up to $400 million from funds managed by Oxford Finance LLC and Hercules Capital, Inc. The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma's continued growth, including the planned commercial launch of ensifentrine, Verona Pharma's first-in-class product candidate, which is under review by the U.S. FDA for the maintenance treatment of COPD
In December 2023, AstraZeneca India, a science-led biopharmaceutical company, announced that it has received Central Drugs Standard Control Organisation (CDSCO) approval to market its inhalation aerosol, a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) for maintenance treatment of COPD.
In September 2023, Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it has completed the acquisition of Physio-Assist SAS, expanding the company's innovative respiratory portfolio.
In April 2022, GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for COPD patients in a once-daily regime.
In June 2021, Verona Pharma Plc. and Nuance Pharma Limited announced that the companies have entered into an agreement granting Nuance Pharma, a Shanghai-based specialty pharmaceutical company, the rights to develop and commercialize ensifentrine in Greater China. Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4. This dual inhibition enables it to combine both bronchodilator and anti-inflammatory effects in one compound.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2022 to 2032 to identify the prevailing emphysema treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.
Emphysema Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 8.7 billion |
 Growth Rate | CAGR of 3.3% |
 Forecast period | 2022 - 2032 |
 Report Pages | 310 |
 By End User |
|
 By Treatment Type |
|
 By Type |
|
 By Region |
|
 Key Market Players | Verona Pharma Plc., Inogen, Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Novartis AG, Viatris Inc., Orion Corporation, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., Koninklijke Philips N.V. |
Analyst Review
Surge in research and development and subsequent product approvals stand as pivotal drivers propelling the emphysema treatment market. As pharmaceutical companies and research institutions increasingly invest in understanding the intricate mechanisms underlying emphysema and its progression, there has been a notable expansion in the development of innovative treatment options. For instance, in December 2023, AstraZeneca India, a science-led biopharmaceutical company, announced that it has received Central Drugs Standard Control Organisation (CDSCO) approval to market its inhalation aerosol, a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg). The pressurized metered dose inhaler is recommended for the treatment and maintenance of patients with COPD. Furthermore, in April 2022, GlaxoSmithKline announced the launch of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for COPD patients in a once-daily regime.
Moreover, the past few years, advancements in treatment modalities have been notable, driven by an increasing emphasis on personalized medicine and innovative therapies. Traditional treatments such as bronchodilators and inhaled corticosteroids remain foundational in managing symptoms and improving quality of life. However, the emergence of approaches, including lung volume reduction and lung transplantation, are gaining traction, especially for severe cases. Overall, the emphysema treatment market is expected to register significant growth owing to rise in R&D and adoption of the therapeutic interventions such as lung volume reduction and lung transplantation.
The total market value of Emphysema Treatment Market is $6,303.98 million in 2022.
The forecast period for Emphysema Treatment Market is 2023-2032.
The market value of Emphysema Treatment Market in 2032 is expected to be $8,739.69 million.
The base year is 2022 in Emphysema Treatment Market.
Major key players that operate in the Emphysema Treatment Market are GlaxoSmithKline, Astrazeneca, Boehringer Ingelheim, and Novartis AG.
The medication segment is the most influencing segment in the emphysema treatment market.
The emphysema treatment market growth is driven by rise in incidence of emphysema and surge in number of smokers globally.
Emphysema is a chronic condition characterized by damage to the air sacs (alveoli) in the lungs, leading to difficulty in breathing.
Loading Table Of Content...
Loading Research Methodology...
